Lipoprotein(a) linked to aortic stenosis onset, but targeted therapy unproven

A 2026 narrative review concludes that genetic, imaging and clinical evidence supports a causal role for elevated lipoprotein(a), or Lp(a), in the initiation of calcific aortic stenosis, while evidence that it drives progression of established severe disease is less consistent. Higher Lp(a) has been associated with faster hemodynamic deterioration in selected cohorts, particularly younger patients, but no completed clinical trial has yet shown that lowering Lp(a) prevents or slows the disorder. An ongoing randomized trial of pelacarsen is the first dedicated test of whether targeted Lp(a) suppression can modify the course of valve disease.

Calcific aortic stenosis is a progressive disorder in which the aortic valve leaflets thicken, accumulate fibrous tissue and become mineralized. Mechanical stress concentrated on the endothelial surface of the leaflets can disrupt the barrier and permit apoB-containing lipoproteins to enter and accumulate in valve tissue. The process is active biological remodeling rather than passive degenerative wear: endothelial injury, inflammation, extracellular-matrix changes, fibrosis and osteogenic signaling can begin decades before clinically detectable narrowing emerges. Once severe symptomatic stenosis develops, surgical or transcatheter aortic valve replacement remains the intervention capable of improving long-term prognosis. No pharmacological treatment has been proven to prevent calcific aortic stenosis or reliably slow hemodynamic worsening after lesions have formed.

Lp(a) is a genetically regulated lipoprotein with an LDL-like core containing apolipoprotein B-100, covalently linked to apolipoprotein(a), or apo(a). Variations in the LPA gene and the number of repeated kringle IV type 2 domains in apo(a) produce wide differences in circulating concentrations among individuals and populations. Smaller apo(a) isoforms are generally associated with higher Lp(a) levels. Approximately one-fifth of the global population exceeds commonly accepted high-risk thresholds, although the distribution differs markedly by ancestry: average concentrations are highest among Black populations, intermediate among Hispanic and South Asian groups and lowest among East Asian and White populations. Age, dietary habits and routine lifestyle modifications have comparatively little influence on the largely genetically determined concentration, although chronic kidney disease, inflammatory disorders, hepatic dysfunction and hormonal fluctuations can alter measurements in some subgroups.

Measurement itself requires care. Mass assays and molar assays do not yield directly interchangeable results because particle mass depends on apo(a) isoform size, and conversion factors vary among laboratories and platforms. The review notes that contemporary lipid-management guidance recommends a one-time Lp(a) test for adults, but Lp(a) is not presently a stand-alone diagnostic biomarker for calcific aortic stenosis, and no validated algorithm based on it dictates the timing of echocardiographic surveillance or valve replacement. In patients with the disorder, the measurement may be particularly informative in people with premature valve calcification, a family history of calcific aortic stenosis or premature atherosclerotic cardiovascular disease, unexpectedly rapid stenosis progression, or residual cardiovascular risk despite well-controlled LDL cholesterol. Conventional management of modifiable cardiovascular risks remains necessary because lifestyle and LDL-lowering strategies cannot substantially reduce genetically determined Lp(a).

The strongest proposed mechanism begins with oxidized phospholipids. Lp(a) is the primary carrier of circulating oxidized phospholipids in human plasma, and these molecules can activate valvular endothelial cells, recruit monocytes, stimulate inflammatory cytokine secretion and promote proliferative signaling in valve interstitial cells. Among patients with mild-to-moderate calcific aortic stenosis, higher Lp(a) and oxidized-phospholipid apoB levels have been associated with steeper increases in peak aortic jet velocity and greater risks of aortic valve replacement or cardiac mortality. Imaging studies have also found greater fluorine-18 sodium fluoride uptake, a marker of active microcalcification, among patients with elevated Lp(a). Cell experiments find that Lp(a) drives osteogenic transformation of human valve interstitial cells, while neutralizing oxidized phospholipids attenuates mineralization. These results support a pathway connecting systemic particles to local disease, but oxidized phospholipids also circulate on other apoB-containing lipoproteins and can be generated within diseased valves, leaving the relative contributions unresolved.

A second pathway involves autotaxin, an enzyme enriched in circulating Lp(a) that converts lysophosphatidylcholine into lysophosphatidic acid. Autotaxin can also be synthesized locally by valve interstitial cells. In explanted calcified human valves, autotaxin colocalizes spatially with apo(a) and oxidized-phospholipid deposits. Experimental studies indicate that lysophosphatidic acid activates nuclear factor-kappa B, interleukin-6 and bone morphogenetic protein signaling, amplifying inflammatory responses and promoting hydroxyapatite crystal deposition within valve tissue. Autotaxin inhibition has attenuated valve calcification in preclinical work, but these findings remain predominantly experimental and do not establish a human clinical benefit. Autotaxin and lysophosphatidic acid are not exclusive to Lp(a), so the pathway is better understood as part of a broader lipid-inflammatory network than as a uniquely Lp(a)-specific mechanism. The central model nevertheless links Lp(a) retention, oxidized-phospholipid delivery, autotaxin-lysophosphatidic acid signaling and osteogenic reprogramming of valve interstitial cells.

The clinical evidence is strongest for disease initiation rather than progression of established severe stenosis. LPA variants that raise Lp(a), including rs10455872 and rs3798220, have been associated with aortic valve calcification and incident obstructive stenosis, while Mendelian randomization studies and prospective cohorts support a population-level causal relationship. Because germline variants predate disease onset, these analyses are less vulnerable to reverse causation than ordinary observational associations. A 2024 individual-participant meta-analysis pooling five longitudinal cohorts reported that participants in the highest Lp(a) tertile had 41% faster progression of peak aortic jet velocity and 57% steeper increases in mean transvalvular gradient than those in the lowest tertile. Post-hoc findings from the ASTRONOMER trial suggest that excess risk associated with high Lp(a) and oxidized phospholipids is more pronounced in younger adults. The relative contribution of Lp(a) may be diluted in older patients with extensive fibrosis, macrocalcification, chronic kidney disease, hypertension and other comorbidities.

Those stage-dependent findings have not been uniform. One long-term population cohort found that Lp(a) predicted the onset of aortic valve calcium but not calcium-score progression among people who already had lesions. Differences in assay platforms, risk thresholds, baseline stenosis severity, imaging endpoints, participant ages and follow-up durations complicate comparisons across studies. The review therefore grades the evidence as strong for incident valve calcification and development of clinical aortic stenosis, moderate for hemodynamic progression and the need for valve replacement, weak and heterogeneous for progression of established calcification, and limited for mortality. This grading is a qualitative assessment of consistency and evidence quality, not a quantified effect size. The review searched PubMed and MEDLINE through 25 July 2026 and prioritized landmark randomized trials, prospective cohorts, Mendelian randomization studies and recent meta-analyses, but it did not use a preregistered protocol or formal systematic-review methods. Its synthesis is therefore a narrative assessment rather than a comprehensive quantitative estimate of every association.

Existing lipid-lowering trials illustrate the difficulty of translating pathway biology into valve outcomes. The SALTIRE, SEAS and ASTRONOMER randomized trials failed to slow progression of established calcific aortic stenosis with statin-centered treatment, although lipid pathways may participate during the earlier priming phase. PCSK9 inhibitors produce much larger reductions in LDL cholesterol and typically lower Lp(a) by approximately 20% to 30%. An exploratory FOURIER analysis linked baseline Lp(a) with incident aortic stenosis and produced a preliminary risk-reduction signal after the first treatment year, but the analysis was not prospectively designed around valve endpoints, had few events and changed both Lp(a) and LDL cholesterol. It therefore cannot establish that Lp(a) lowering modifies stenosis. Lipoprotein apheresis can reduce Lp(a) acutely by roughly 60% to 75%, but concentrations rebound rapidly between sessions, the intervention requires substantial resources, and robust evidence that it slows valve disease is absent.

More selective therapies have achieved much larger biomarker reductions without yet proving clinical benefit for calcific aortic stenosis. Pelacarsen, a hepatocyte-directed antisense oligonucleotide that suppresses apo(a) production, reduced Lp(a) by as much as 80% in phase 2 studies among participants with pre-existing cardiovascular disease. The small interfering RNA olpasiran exceeded 95% reduction at higher phase 2 doses; lepodisiran produced more than 90% reduction with prolonged effects, and zerlasiran lowered time-averaged concentrations by more than 80%. The oral assembly inhibitor muvalaplin produced dose-dependent reductions of up to roughly 86% over 12 weeks in phase 2 testing. These results demonstrate that Lp(a) can be suppressed, but no completed trial has shown that the biomarker change translates into slower valve calcification or better clinical outcomes. The double-blind, placebo-controlled Lp(a)FRONTIERS CAVS trial is recruiting an estimated 502 patients with calcific aortic stenosis to test monthly pelacarsen directly, with primary trial completion projected for March 2030. Whether treatment works may depend on disease stage, treatment duration, the magnitude of suppression and the biomarkers that best predict response; future trials will need to distinguish disease prevention from modification of established stenosis, recruit diverse populations, standardize assays and combine imaging measures with clinical outcomes.

Subject of Research: Lipoprotein(a) as a causal factor and therapeutic target in calcific aortic stenosis

Article Title: Lipoprotein(a) in calcific aortic stenosis: mechanistic insights, clinical evidence, and emerging therapies

Article References: Li, W., Shuang, S. Y., An, Y. B., Yao, X., Hao, W., Sheng, X. X., Lian, P. X., & Feng, M. Q. (2026). Lipoprotein(a) in calcific aortic stenosis: mechanistic insights, clinical evidence, and emerging therapies. Frontiers in Cardiovascular Medicine, 13, Article 1963618. https://doi.org/10.3389/fcvm.2026.1963618

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1963618

Keywords: lipoprotein(a), calcific aortic stenosis, aortic valve calcification, oxidized phospholipids, autotaxin, pelacarsen, Lp(a) lowering, LPA gene, valve inflammation, clinical trials, Lipoprotein, calcific